Enanta Pharmaceuticals, Inc. cash flow to debt ratio of -9.59% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Enanta Pharmaceuticals, Inc.'s free cash flow has increased -66.74% from $-96.71M last year to $-32.17M, signaling increasing performance

Enanta Pharmaceuticals, Inc.'s debt to equity ratio is 0.55, which means that the company's assets are healthy financed, signaling financial stability.

Enanta Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 1.75 last year to 0.55 today, signaling strengthened financials

Enanta Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

Enanta Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Enanta Pharmaceuticals, Inc.'s profit margin has increased (-43.53%) in the last year from -171.58% to -96.89%, signaling increasing performance

Enanta Pharmaceuticals, Inc.'s short-term assets of $204.34M exceed its short-term liabilities of $48.55M

Enanta Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Enanta Pharmaceuticals, Inc.'s return on equity of -61.84%, is lower than 15.00%, indicating bad performance

Enanta Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Enanta Pharmaceuticals, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Enanta Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Enanta Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

Enanta Pharmaceuticals, Inc.'s yearly earnings has increased -29.43% since last year from $-116.05M to $-81.89M, signaling increasing performance

Enanta Pharmaceuticals, Inc.'s yearly revenue has decreased 3.42% since last year from $67.64M to $65.32M, signaling decreasing performance

ROIC -23.81% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Enanta Pharmaceuticals, Inc.'s 3-year revenue CAGR of -8.82% is negative, indicating declining revenue over the past 3 years

Enanta Pharmaceuticals, Inc. had revenue growth in only 0 out of 5 years, indicating inconsistent revenue performance

Enanta Pharmaceuticals, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Enanta Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Enanta Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Enanta Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Enanta Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Enanta Pharmaceuticals, Inc. is overvalued relative to its fair value price of -29.55 based on Earnings Fair Value model

Enanta Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Enanta Pharmaceuticals, Inc. has a price-to-book ratio of 3.97x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Enanta Pharmaceuticals, Inc. has a price-to-sales ratio of 6.16x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue